Welcome to our dedicated page for KANE BIOTECH news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH stock.
Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Kane Biotech (KNBIF) will host a virtual Commercial Update webcast on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time.
The approximately 60-minute event will include presentations from Board Chair Philip Renaud, interim CEO Dr. Robert Huizinga and wound-care surgeon Dr. John C. Lantis, followed by a question-and-answer session. The webcast will review Kane’s progress in building a clinically credible, commercially focused wound-care business and its strategy to drive recurring revenue from its U.S. FDA 510(k) cleared and Health Canada approved revyve antimicrobial wound-care portfolio. A replay will be available on the company’s website after the event.
Kane Biotech (KNBIF) entered a non-exclusive Canadian distribution agreement with Ottawa-based Ontario Medical Supply (OMS) for its revyve antimicrobial wound care products.
OMS will purchase, market and support U.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, while Kane provides product training and sales materials. OMS is one of only two authorized distributors and price agreement holders for Ontario Health atHome, which coordinates publicly funded home and community care for more than 680,000 patients and delivered 11.1 million nursing visits in Ontario in 2024–25. Published estimates indicate wound care may account for roughly 40–50% of home-care nursing visits, underscoring a substantial wound care burden. The agreement establishes a framework for ordering, training, customer support, quality management, traceability and complaint reporting, which the company says supports its strategy to expand access to revyve across Canada.
Kane Biotech (OTC:KNBIF, TSX-V:KNE) reported second quarter 2026 revenue of $8,143, down from $27,997 a year earlier, reflecting its transition from legacy animal health and DermaKB lines to early-stage commercialization of its revyve antimicrobial wound care portfolio in Canada and the United States.
Gross profit improved to $1,444 from a gross loss of $(45,526), while operating expenses rose to $785,927 from $229,930, largely due to stock option expense and prior-year compensation reversals. Net loss widened to $(833,636) versus $(348,541), and cash at June 30, 2026 was $854,729, according to Kane Biotech.
Kane Biotech highlighted ongoing commercialization efforts for revyve, including distributor expansion, clinical evaluations at multiple North American sites, a new Scientific Advisory Board, manufacturing scale-up activities, and plans to initiate DispersinB Hydrogel biocompatibility testing in the third quarter of 2026.
Kane Biotech (OTCQB:KNBIF, TSX-V:KNE) reported that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. The talk addressed potential uses in prolonged field care and military wound management, especially in austere environments where access to advanced medical care may be delayed.
The presentation, titled “Broad-Spectrum, Cavity-Filling Antimicrobial Gel Spray to Address Prolonged Field Care Wound Challenges,” highlighted revyve Antimicrobial Wound Gel Spray, which is U.S. FDA 510(k) cleared and Health Canada approved. According to Kane, clinicians expressed interest in revyve’s antimicrobial, antibiofilm, and cavity-filling properties and its contactless, rapid delivery.
Following MHSRS, several researchers approached Kane to explore revyve in military, prolonged field care, and complex wound settings, and the company is collaborating with them to develop a clinical research plan. Kane continues commercialization of the revyve product portfolio and sees military and government healthcare channels as a potential long-term opportunity.
Kane Biotech (OTC:KNBIF) has engaged DNA Advisors as its exclusive financial advisor to conduct a comprehensive review of strategic opportunities intended to enhance shareholder value and support long-term growth. According to Kane, the review will consider strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations and other corporate transactions.
The company highlights that its revyve-branded Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray have received FDA 510(k) clearance in the United States and Health Canada approval, with commercial activities in both countries commencing in 2026, supported by added senior business development personnel. Kane emphasizes that there is no assurance the review will result in any specific transaction and has not set a completion timetable, stating it will only announce outcomes once a course of action is approved or disclosure is required by securities laws.
Kane Biotech (OTC:KNBIF) reported voting results from its June 24, 2026 annual and special shareholder meeting. About 83,622,028 shares, or 46% of outstanding common shares, were represented. All resolutions passed, including election of six directors, auditor appointment, and two equity-based compensation plans.
Shareholders approved a PRSU plan reserving 18,185,656 shares (10%) and a rolling stock option plan allowing issuance up to 10% of outstanding shares at grant.
Kane Biotech (OTC:KNBIF) reported Q1 2026 revenue of $43,218, down from $412,513 a year earlier, reflecting its transition from legacy animal health to focused human wound care and early commercialization of revyve.
Gross loss was $3,899, operating expenses fell to $669,402, and net loss improved to $714,827. Cash was $395,058, with a subsequent $1.16 million private placement. Kane expanded North American distribution, gained U.S. FDA 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, advanced clinical validation, and extended ISO 13485:2016 certification.
Kane Biotech (OTC:KNBIF) participated in the WCET–NSWOCC 2026 Joint Congress in Vancouver as an exhibitor and presenter, focusing on its revyve Antimicrobial Wound Gel, which is FDA cleared and authorized for sale in Canada.
The company presented a clinical case study on a complex diabetic foot ulcer, showing how rebalancing the wound environment supported progression toward healing and potentially improved quality of life. Kane Biotech engaged with global wound care clinicians, emphasizing education on biofilm, chronic wound challenges, and integrating antimicrobial approaches like revyve into standard care as part of its commercialization and global education strategy.
Kane Biotech (OTC:KNBIF) reported FY2025 revenue of $427,869 versus $2,080,879 in 2024 and a FY2025 net loss from continuing operations of $2,721,239. Cash at December 31, 2025 was $901,698. The company completed restructuring, closed multiple private placements and converted an insider loan to a five-year convertible debenture.
Regulatory and commercial progress includes Health Canada approval for revyve Gel Spray, U.S. FDA 510(k) clearance for revyve cleanser, new U.S. distribution agreements, and initial product shipments under a Marathon Medical partnership.
Kane Biotech (OTC:KNBIF) presented case-study clinical data for revyve at the SAWC Spring conference (April 8-12, 2026).
Highlights include >20-year venous leg ulcers reduced 85% at 33 weeks, complete pain elimination by week 6, 90% wound volume reduction in seven months for a tunneling wound, and wound pH falling from 8.0 to 6.8 in four weeks.